11/15
04:05 pm
acad
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/15
12:02 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Medium
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/12
11:56 am
acad
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock [Yahoo! Finance]
Low
Report
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock [Yahoo! Finance]
11/11
10:53 am
acad
Acadia Pharmaceuticals: Proving The Naysayers Wrong [Seeking Alpha]
Low
Report
Acadia Pharmaceuticals: Proving The Naysayers Wrong [Seeking Alpha]
11/9
08:10 am
acad
ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next [Yahoo! Finance]
Low
Report
ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next [Yahoo! Finance]
11/7
11:47 am
acad
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth [Yahoo! Finance]
Low
Report
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth [Yahoo! Finance]
11/7
08:36 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Medium
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
11/7
08:36 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Medium
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
11/7
06:17 am
acad
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... [Yahoo! Finance]
Medium
Report
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... [Yahoo! Finance]
11/6
05:28 pm
acad
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview [Yahoo! Finance]
Medium
Report
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview [Yahoo! Finance]
11/6
04:13 pm
acad
Acadia Pharma GAAP EPS of $0.20 beats by $0.06, revenue of $250.4M beats by $1.56M Nov. 06, 2024 4:09 PM ET By: Urvi Shah , SA News Editor [Seeking Alpha]
Medium
Report
Acadia Pharma GAAP EPS of $0.20 beats by $0.06, revenue of $250.4M beats by $1.56M Nov. 06, 2024 4:09 PM ET By: Urvi Shah , SA News Editor [Seeking Alpha]
11/6
04:05 pm
acad
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
Medium
Report
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
11/5
04:05 pm
acad
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
Medium
Report
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
10/17
06:46 pm
acad
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 [Yahoo! Finance]
10/17
06:41 pm
acad
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
Low
Report
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
10/16
04:10 pm
acad
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome [Yahoo! Finance]
10/16
04:07 pm
acad
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
Low
Report
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
10/14
01:26 pm
acad
Why Acadia (ACAD) Could Beat Earnings Estimates Again [Yahoo! Finance]
Low
Report
Why Acadia (ACAD) Could Beat Earnings Estimates Again [Yahoo! Finance]
10/14
07:05 am
acad
Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? [Yahoo! Finance]
Low
Report
Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? [Yahoo! Finance]
10/10
09:36 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "market perform" rating re-affirmed by analysts at Raymond James.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "market perform" rating re-affirmed by analysts at Raymond James.
10/9
01:00 pm
acad
ACAD or TECH: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Low
Report
ACAD or TECH: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
10/8
04:05 pm
acad
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/7
04:07 am
acad
Ushering in a new era of fit-for-purpose clinical endpoints for Rett syndrome [Yahoo! Finance]
Low
Report
Ushering in a new era of fit-for-purpose clinical endpoints for Rett syndrome [Yahoo! Finance]
9/26
04:05 pm
acad
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/23
04:15 pm
acad
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
Medium
Report
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals